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Abstract
Background: Multidrug antiretroviral (ARV) regimens including HAART and short-course dual antiretroviral (sc-dARV)
regimens were introduced in 2004 to improve Prevention of Mother-to-Child Transmission (PMTCT) in Cameroon. We
assessed the effectiveness of these regimens from 6–10 weeks and 12 months of age, respectively.
Methodology/Findings: We conducted a retrospective cohort study covering the period from October 2004 to March 2008
in a reference hospital in Cameroon. HIV-positive pregnant women with CD4 #350 cells/mm
3 received first-line HAART
[regimen 1] while the others received ARV prophylaxis including sc-dARV or single dose nevirapine (sd-NVP). Sc-dARV
included at least two drugs according to different gestational ages: zidovudine (ZDV) from 28–32 weeks plus sd-NVP
[regimen 2], ZDV and lamuvidine (3TC) from 33–36 weeks plus sd-NVP [regimen 3]. When gestational age was $37 weeks,
women received sd-NVP during labour [regimen 4]. Infants received sd-NVP plus ZDV and 3TC for 7 days or 30 days. Early
diagnosis (6–10 weeks) was done, using b-DNA and subsequently RT-PCR. We determined early MTCT rate and associated
risk factors using logistic regression. The 12-month HIV-free survival was assessed using Cox regression. Among 418
mothers, 335 (80%) received multidrug ARV regimens (1, 2, and 3) and MTCT rate with multidrug regimens was 6.6% [95%CI:
4.3–9.6] at 6 weeks, without any significant difference between regimens. Duration of mother’s ARV regimen ,4 weeks
[OR=4.7, 95%CI: 1.3–17.6], mother’s CD4 ,350 cells/mm
3 [OR=6.4, 95%CI: 1.8–22.5] and low birth weight [OR=4.0, 95%CI:
1.4–11.3] were associated with early MTCT. By 12 months, mixed feeding [HR=8.7, 95%CI: 3.6–20.6], prematurity [HR=2.3,
95%CI: 1.2–4.3] and low birth weight were associated with children’s risk of progressing to infection or death.
Conclusions: Multidrug ARV regimens for PMTCT are feasible and effective in routine reference hospital. Early initiation of
ARV during pregnancy and proper obstetrical care are essential to improve PMTCT.
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Introduction
Infection due to Human Immunodeficiency Virus type 1 (HIV-1)
is oneofthemaincausesofmorbidityandmortalityamongchildren
in Africa [1,2]. By the end of 2007, 33.2 million people were living
with HIV/AIDS in the world, of whom about 2.5 million were
children under 15 years [3]. More than 95% of all HIV-infected
children are living in Africa, and most of them have acquired HIV
through Mother-To-Child Transmission (MTCT) [4,5]. In the
absence of interventions to prevent MTCT of HIV-1, transmission
rates can reach 40% in breastfeeding populations [6]. Global
estimationsin2007showthat 1,500childrenwereinfectedeveryday
by HIV-1 and that 330,000 deaths in children were due to AIDS-
related conditions [3].
However, in most cases, a number of preventive measures are
available to drastically reduce cases of MTCT of HIV-1. In most
developed countries and some middle-income countries, such as
Brazil and Thailand, implementation of effective strategies
including Highly Active Antiretroviral Therapy (HAART) with
scheduled caesarean sections and avoidance of breastfeeding have
reduced MTCT rate to below 2% [3,4]. In resource-constrained
settings, elective caesarean delivery is seldom feasible [7] and it is
often neither acceptable nor safe for mothers to refrain from
breastfeeding. In these settings, initial efforts to prevent HIV
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period of labour and delivery, which accounts for one to two thirds
of the overall transmission, depending on whether the mother
breastfeeds or not. Antiretroviral (ARV) prophylaxis around the
time of delivery alone can reduce the risk of MTCT in a
breastfeeding population to almost two-fold following vaginal
delivery (41–47% reduction in risk) [8,9]. Further studies in sub-
Saharan Africa demonstrated that multidrug ARV regimens had
greater efficacy than sd-NVP [2,10]. MTCT rates as low as 5.6%
was reported with short-course (sc) multidrug ARV regimens
combined with shortened breastfeeding in a research setting in
Abidjan [11].
In 2004, WHO revised recommendations for the use of
antiretroviral drugs for treating pregnant women and preventing
HIV infection in infants, stipulating that pregnant women who
need HAART for their own health should receive first-line ARV
regimens as soon as possible during pregnancy. HIV-infected
pregnant women without indications for antiretroviral treatment
should mainly receive ARV regimen including zidovudine (ZDV)
starting from 28 weeks of pregnancy plus sd-NVP and ZDV
during labour, and sd-NVP plus ZDV for one week should be
given to the infant [12]. Programmatic considerations and health
systems constraints in most high-burden countries should be taken
into consideration while adapting ARV guidelines for national
PMTCT programmes. However, little information on field
effectiveness of the 2004 WHO guidelines is available in the
literature.
With a prevalence of HIV among pregnant women estimated at
7.3% in 2007 [3], about 20,000 new HIV infections in infants are
expected each year in Cameroon without any intervention. A pilot
PMTCT initiative supported by the Glaxo Smith Kline Founda-
tion started in year 2000 and reported a MTCT rate of 13.1% at
24 months using the HIVNET-012 sd-NVP regimen [13]. The
national PMTCT program was launched in 2002 based on the
early results of this pilot initiative, and maternal and infant sd-
NVP was recommended as first choice PMTCT regimen. In 2004,
following preliminary results from the ‘‘ANRS 1201/1202 trial’’
reported in 2002 and according to revised WHO guidelines, the
Cameroonian Ministry of Health revised the national guidelines
for PMTCT and recommended treatment with HAART for HIV-
positive pregnant women with CD4 counts #350 cells/mm3 and
short-course combination regimens for pregnant women without
indication of treatment. In 2007, a demonstrative program carried
out in Abidjan reported a safe and highly effectiveness of HAART
and sc ARV regimens [14]. However, data were still lacking on the
routine effectiveness of these new regimens in a resource-
constrained setting and should ideally be reported as early as
possible. The hypothesis assessed in this study was that the
implementation of the revised multidrug ARV regimens for
PMTCT would result in routine in transmission rates decreasing
from 13.1% (as earlier reported in Yaounde with sd-NVP regimen
[13]) to a value which could be close to 6% (the value reported in
Abidjan between 2001 and 2005 [15]). We report a 6–10 weeks
and 12 months effectiveness of the new regimens in a day-to-day
practice in a reference hospital in Yaounde, Cameroon.
Methods
Study site
The study was conducted at the ‘‘Caisse Nationale de
Prevoyance Sociale (CNPS)’’ hospital, a reference semi-private
health facility in Yaounde, Cameroon, where PMTCT was
implemented since 2000. The prevalence of HIV infection among
pregnant women in Yaounde was estimated around 8% in 2004
[16]. Pregnant women received at the CNPS were characterised
by their interest and willingness to use existing PMTCT services in
this reference hospital. These included all pregnant women who
consulted during the study period and were diagnosed HIV
positive during ANC visits, and known HIV-positive women who
became pregnant and attended ANC visits at this hospital during
the consider time. Children involved in the study were those born
to the above mentioned groups of women. In this structure, the
PMTCT package proposed include the following: Voluntary
counselling and testing ‘‘opt out’’, clinical and immunological
assessment of women identified as HIV-infected, HAART or ARV
prophylaxis, safer delivery practices, counselling and care related
to nutrition (exclusive formula feeding or shortened breastfeeding)
and psychosocial support, early HIV-diagnosis of children and
follow-up of exposed children up to 12 months.
Study design
We conducted a retrospective cohort study nested within a
routine PMTCT program implemented according to national
guidelines. The period covered by this study was October 2004 to
March 2008.
Study population
HIV-positive pregnant women aged 18 years and older, who
had received ARV (sd-NVP, sc-dARV and HAART) at the CNPS
hospital, were eligible for the study with their neonates. These
children had received ARV drugs at birth, and had been followed-
up between birth and 12 months of age. None of the participating
women were involved in any clinical trial during the study period.
Exclusion criteria from the study included being a second twin or a
third triplet since studies have reported a lower MTCT risk for
second twins and third triplets [17].
To assess the effectiveness of the new recommendations, it is
important for the study to have a sufficient statistical power to
demonstrate that there is a significant difference between the
expected transmission rate and the transmission rate observed
earlier. The minimal sample size for this comparison between
expected MTCT rate (which can go down to 6%) and the
observed MTCT rate (13.1%) is 223 mother-child pairs. Since files
were accessible, we included more participating women who met
the eligibility criteria than the minimal size required.
Antiretroviral interventions to prevent MTCT of HIV
CD4 cell counts of enrolled patients were performed using the
flow cytometry technique (Becton Dickinson FACSCount
TM
System). From October 2004 to August 2006, HIV-positive
pregnant women with CD4 counts inferior to 200 cells/mm
3 were
eligible to receive HAART (according to current national
guidelines) referred in this report as regimen 1. The regimen 1
included ZDV+3TC+NVP or D4T+3TC+NVP. HIV-positive
pregnant women with CD4 count $200 cells/mm
3 received short-
course dual antiretroviral (sc-dARV) regimens, comprising short-
course zidovudine (sc ZDV) in antepartum and sd-NVP during
labour, or short-course of zidovudine+lamivudine (sc ZDV+3TC)
in antepartum and sd-NVP during labour. Some women of the
latter group did not receive ARV in antepartum. These ARV
regimens were initiated depending on the gestational ages of
pregnancies calculated from the last menstrual period: 28–32
weeks [regimen 2; sc ZDV in antepartum+sd-NVP and ZDV/
3TC during labour+7 days ZDV/3TC in post partum]; 33–36
weeks [regimen 3; sc (ZDV/3TC) in antepartum+sd-NVP during
labour+7 days ZDV/3TC in post partum] and 37 weeks or older
[regimen 4; sd-NVP during labour+7 days ZDV/3TC in post
partum]. Infants received sd-NVP+7 days ZDV (or ZDV+3TC) as
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ZDV+3TC) if the mother had not received ARV during antenatal
period. Between September 2006 and March 2008, the CD4
count threshold for HAART eligibility was raised to 350cells/
mm
3, but the ARV regimens remained unchanged. All regimens
were administered orally. In addition, all women received
individual counselling on feeding practices as recommended by
WHO. Women who chosed replacement feeding were educated
on safe formula preparation and administration. Psychosocial
support was offered. Apart from scheduled visits, no specific
strategy to document compliance was developed.
Follow up of participants
PMTCT interventions were administered at the antenatal
clinic, laboratory, maternity and paediatric services. These services
involved physicians, counsellors (voluntary HIV testing and
nutrition), mid-wives, psychologists and social workers. Pregnant
women were seen every month if the gestational age was 28–36
weeks, and every two weeks beyond 36 weeks. All women were
encouraged to deliver in health facilities.
At birth, all children were examined by a paediatrician before
discharged from the hospital. During the first visit between 6–10
weeks, in addition to clinical, psychological and nutritional follow-
up, early diagnosis of HIV-1 infection was proposed. Before 2007,
HIV diagnosis was performed by quantification of viral RNA in
plasma samples using the branched DNA (b-DNA) technique
(Bayer Diagnostics, Paris, France). In 2007, a real time PCR (RT-
PCR) using the TaqMan technology, an in-house protocol
validated by the French ‘‘Agence Nationale de Recherche sur le
Sida et les he ´patites virales’’ (ANRS, AC 11 working group,
France) replaced the b-DNA technique. Diagnosis was performed
by the virology laboratory of the Centre Pasteur du Cameroun.
Positive results were confirmed with a second infant specimen. All
infants who were diagnosed with an early HIV-1 infection and
who came back to the clinic were enrolled into the care and
treatment program and initiated the antiretroviral therapy. After
the first visit (6–10 weeks), children were followed every month
until the age of 4 months and every trimester through the age of 15
months. At each visit, clinical and nutritional assessments were
performed. Mothers were strongly encouraged to bring their
children to hospital if there was any medical incident. For children
aged from 9 to 12 months, peripheral blood was obtained at least
three months after cessation of breastfeeding (when this was the
feeding option) and tested for HIV using ELISA (enzyme-linked
immunosorbent assay) technique. All confirmed HIV-positive
children who returned for results were systematically enrolled into
the care and treatment program and initiated on HAART.
Study end points
The primary end point was HIV infection through the
scheduled 6-week visit window (diagnosis made between 6 and
10 weeks). By 12 months of age, children were either HIV
infected, uninfected, lost to follow-up or dead. The composite end
point was HIV-free survival through to 12 months with a visit
window which could go up to two weeks.
Data collection
At each scheduled visit, information on infant’s feeding practice,
morbidity; mortality and all clinical events up till the age of one year
were documented using patient files or registers. A questionnaire
was designed to collect mother-infant pair’s variables. Information
missing in the medical files was abstracted from service registers.
Feeding practice variables were defined according to the following:
children whose mothers reported exclusive breastfeeding at each
scheduled visit between birth and 6 months were considered as
exclusively breastfed; children whose mothers reported exclusive
formula feeding at each scheduled visit between birth and 6 months
were considered as exclusively formula-fed; and children whose
mothers reported simultaneous breastfeeding and formula feeding
or interrupted periods of breastfeeding with formula feeding in an
inconsistent manner were considered as mixed-fed. All recorded
variables were classified as either dependent or independent.
Dependent variables were child HIV status at six week after birth
(infected versus uninfected) and HIV-free survival of children at 12-
month (free of HIV and alive versus infected or dead). Mother-
related independent variables were age, educational level, marital
status, number of pregnancy, parity, premature rupture of
membrane defined as rupture occurring before the beginning of
the labour whatever the moment, mode of delivery, term of
pregnancy (children born before 37 weeks of pregnancy were
considered premature), ARV regimen and its duration, and CD4
cell counts. Children-related independent variables were date of
birth, birth weight, gender, feeding practice at each scheduled visit
between birth and six months, type of ARV regimen and clinical
events between scheduled visits.
Statistical methods
Mothers’ treatment had 4 modalities: regimen 1, 2, 3 and 4.
Mothers were divided into 2 categories according to CD4 counts
during pregnancy: CD4 ,200 cells/mm
3 versus CD4 $200cells/
mm
3 between October 2004 and August 2006; CD4 ,350 cells/
mm
3 versus CD4 $350cells/mm
3 from September 2006 to March
2008. We assumed that feeding practices reported at each visit was
the one effectively done. Bivariate analyses were done using the
Student’s t-test to compare continuous variables and the Chi-
square test to compare categorical variables. A p value,0.05 was
considered significant.
Early HIV infection was used to assess short-term efficacy
(6–10weeks), while HIV-free survival were used to assess long-term
efficacy (12 months) of interventions implemented in routine,
based on international recommendations [18]. Determinants of
infant probability to become infected at 6-week was estimated
using a multivariate logistic regression model [19]. We defined
postnatal transmission as a child with negative HIV PCR from a
sample obtained between 6–10 weeks and who later became
infected. Time to event was defined as the delay between birth and
the occurrence of an event (infection or death) or between birth
and reaching end point. All variables associated to early child
infection in univariate analysis with a significance level,0.20 were
included in the stepwise multivariate analyses, with consideration
for confounding effect and interactions. The final multivariate
model contained the variables with a significance level,0.05, but
some other variables (such as mode of delivery) could be forced
into the model when being considered of particular interest
according to previous studies [11].
For HIV-free survival analysis, the time of the event occurrence
was the date of death or the date when HIV infection was
diagnosed. Data from infants lost to follow-up before reaching
12-month were censored. Probabilities of 12-month HIV-free
survival for children exclusively breastfed, children exclusively
formula-fed or children who practiced mixed feeding were
estimated using the Kaplan-Meier methods with P values
calculated using the log-rank test. Cox proportional hazards
regression models [20] were used to explore determinants of HIV-
free survival at 12-month. The choice of variables to be included
in the final multivariate Cox model was determined using a
backward stepwise procedure. All variables that met the
proportional hazard assumption and associated, in univariate
Multidrug Regimens in PMTCT
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included in the model. The final multivariate model contained the
variables with a significance level,0.05. Data were managed using
Epidata 3.1 software and analyzed using SAS 9.1 software (SAS
Institute Inc., Cary, NC, USA). Analyses were made on an
intention-to-treat basis.
Ethical and administrative aspects
PMTCT interventions at CNPS hospital were implemented
according to the national guidelines of Cameroon, under the
supervision of the Ministry of Public Health (MOH). This
retrospective evaluation of MOH’s recommendations was ap-
proved by the technical medical division (TMD) of the CNPS
hospital, the board in charge of the ethics of practices and research
activities in the CNPS hospital, which gave the authorization.
Results
General characteristics
Between October 2004 and March 2008, 443 mother-infant
pairs were received at the site. Among these pairs, 25 (5.6%) were
considered as unexploitable data because either the children were
lost to follow-up before 6 weeks of age or the files of the mothers
and/or infants were incomplete. 418 eligible mothers with their
children were retained for analysis. The median age of mothers
was 27 years (interquartile range [IQR] 24–30 years). More than
74% (310/418) of them had at least secondary school level
education, 68% were experiencing their first pregnancy or had
only one previous delivery. Of 418 enrolled women, 73 (17.5%)
had received regimen 1 at a median gestational age of 32 weeks,
163 (38.9%) had received regimen 2, 99 (23.7%) had received
regimen 3 and 83 (19.9%) had received regimen 4. During
pregnancy, CD4 cell counts were done in the weeks that followed
the diagnosis of HIV or following the first ANC visit for known
HIV-positive women. The median CD4 count was 380cells/mm
3
(IQR 310–450cells/mm
3). Thirty-six women (8.6%) delivered
through caesarean section. Among the 418 live births, 11.2% were
born to mothers who had a premature rupture of membranes. The
median weight at birth was 3,000 grams (IQR 2550–3400 grams).
Overall, 22.2% (93/418) had a low birth weight (,2,500 grams)
and 16.3% (68/418) were born before 37 weeks of amenorrhea.
More than 85% (357/418) infants were classified as exclusively
formula-fed (EFF), 9.1% (38/418) were classified as exclusively
breastfed (EBF) and 5.5% (23/418) were classified as mixed-fed
(MF).
MTCT rates
Early(6–10weeks)MTCTrate of2.7%[2/73;95%CI:0.5–8.8],
7.4% [12/163; 95% CI: 4.1–12.2], 8.1% [8/99; 95% CI: 3.8–14.8]
and 9.6% [8/83; 95% CI: 4.6–17.5] were registered respectively
with regimens 1, 2, 3 and 4 (figure 1). Taking in consideration only
women having received multidrug ARV regimens prior delivery (1,
2 and 3), overall MTCT rate was 6.6% [22/335; 95%CI: 4.3–9.6]
at 6–10 weeks. At 12-months, late cumulative MTCT rate
regardless of regimen type (1 to 4) was 8.1% [32/394; 95%CI:
5.7–11.1]. Postnatal transmission at 12 months was 25% [8/32;
95%IC: 12.4–42] of infected children. This occurred throughout
breastfeeding. Taking into account the changes in HAART
eligibility in the course of the study (October 2004 to August
2006; September 2006 to March 2008), we did not find any
difference in MTCT rate after the use of multidrug regimens (8.1%
Vs 4.6%; p=0.18).
Factors associated with 6–10 weeks MTCT of HIV
In univariate analysis, there was no significant difference in
early MTCT rate between the ARV regimens. Mothers with CD4
counts below 350cells/mm
3 had a fourfold risk (OR: 4.0; 95%CI:
1.7–9.2) of MTCT. The following factors were found to be
Figure 1. Flowchart describing regimens received and MTCT rates at six weeks at the CNPS, Cameroon. Between October 2004 and
March 2008, 443 mother-infant pairs were eligible for the study. Among these, 25 had unexploitable data and 418 were retained for analysis.
doi:10.1371/journal.pone.0010411.g001
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shorter than 4 weeks (OR: 6.6; 95%CI: 2.9–15.3), premature
rupture of membranes (OR: 39.9; 95%CI: 16.2–98.7), low birth
weight (OR: 8.6; 95%CI: 3.9–19.2) and prematurity (OR: 3.9;
95%CI: 1.8–8.7). Except for prematurity, the other variables
associated with early MTCT risk in univariate analysis were still
found to be associated with high MTCT risk in multivariate
analysis (table 1).
Determinants of HIV-free survival
The probability of progressing to infection or death at 12-month
was 17% and the infant mortality rate was 9.1%. Taking into
consideration feeding practices, infant mortality rate was 5.6%
(95%CI: 0.9–17.2), 8.7% (95%CI: 6–12) and 21.7% (95%CI:
8.4–41.8), among children on EBF, EFF and MF respectively
(p,0.001). By twelve month, infant mortality rates were 7.9%
(95%CI: 5.5–11.1) and 20% (95%CI: 8.5–37) among uninfected
and infected children respectively (P,0.001). Mixed-fed children
had poorer survival outcomes by one year of age compare to their
counterpart EBF or EFF (p,0.001) (figure 2). In univariate
analysis, factors associated with an increased risk of being infected
or dead were: duration of treatment shorter than 4 weeks [hazard
ratio (HR): 3.6; 95%CI: 2.2–5.8], mothers on regimen 4 during
pregnancy (HR: 4.2; 95%CI: 1.6–11), prematurity (HR=4.3;
95%CI: 2.6–7.0), low birth weight (HR: 5.0; 95%CI: 3.1–8.1),
EBF (HR=2.8; 95%CI: 1.5–5.4) or mixed feeding (HR=6.9;
Table 1. Determinants of the 6-weeks MTCT Risk (Multivariate logistic regression model), at the CNPS hospital of Yaounde in
Cameroon between 2004 and 2008.
N OR** 95% CI P ORa*** 95% CI P
Duration of treatment
$4 weeks before delivery 306 1 1
,4 weeks before delivery 112 6.6 2.9–15.3 ,0.0001 4.7 1.3–17.6 ,0.0001
Treatment
Regimen 1 (HAART) 73 1 1
Regimen 2 163 2.8 0.6–12.9 0.18 0.5 0.05–4.9 0.5
Regimen 3 99 3.1 0.6–15.2 0.15 1.6 0.2–12 0.6
Regimen 4 83 3.7 0.8–18.4 0.15 2.1 0.2–18.5 0.5
TCD4 Lymphocytes
.350 cells/ml 238 1 1
#350 cells/ml 180 4.02 1.7–9.2 ,0.001 6.4 1.8–22.5 ,0,004
Delivery
Cesarean section 36 1 1
Normal 382 2.9 0.4–21.7 0.30 2.4 0.2–25.9 0.46
Premature rupture of membranes
No 371 1 1
Yes (before onset of labour) 47 39.9 16.2–98.7 ,0.0001 27.6 8.9–84.8 0,0001
Birth weight
.2500 grams 325 1 1
#2500 grams 93 8.6 3.9–19.2 0.0001 4.0 1.4–11.3 0,008
Prematurity*
No 68 1 1
Yes 350 3.9 1.8–8.7 0.01 0.82 0.2–2.9 0.8
*(,37 weeks of gestation).
**Crude (Univariate).
***Adjusted (Multivariate).
doi:10.1371/journal.pone.0010411.t001
Figure 2. Cumulative Survival rates of children by 12 month
according to mode of feeding, Cameroon. Taking in consideration
defined feeding practice variables, survival curves by one year of age in
each group were estimated using Kaplan Meier method. Next, survival
curves between mixed-fed children (lower survival curve) and their
counterpart exclusive formula-fed (middle survival curve) or exclusive
breastfed (upper survival curve) were compared using the log-rank test.
doi:10.1371/journal.pone.0010411.g002
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turity, low birth weight and mixed feeding were still associated
with the probability of progressing to infection or death.
Discussion
Our study was based on a retrospective analysis of data from a
routine PMTCT program in a reference hospital. To the best of
our knowledge, this study presents primary results of the
effectiveness of routine PMTCT interventions in Cameroon since
the implementation of the new recommendations in 2004. Sources
of data were patients’ files and registers used for the monitoring of
the services offered. Unfortunately, some pertinent variables for
building a fully exploratory model such as mother’s HIV-1 viral
load [21], intermittent preventive treatment of malaria (IPT),
child’s vaccine status or prophylaxis with cotrimoxazole were not
systematically recorded and could not be taken into account. The
hospital where the study was carried out was reported to have
good managerial and clinical practices. It was possible to access to
register of the past four years as well as sources of information in
antenatal, maternity, laboratory and paediatric services. All early
HIV diagnosis and TCD4 lymphocytes counts were performed in
the virology laboratory of the Centre Pasteur du Cameroun where
results were stored in a computerized database. Few mother-infant
pairs were excluded from the analysis (lost to follow-up or
unexploitable files). Some of these infants might have been HIV-
infected and this could have led to an overestimate of the
effectiveness of the new regimens. Also, the association between
duration of regimens and MTCT risk similarly could have been
overestimated, since analysis were realised in an intent-to-treat
basis. However, the observations we made in this reference health
facility in Yaounde give reliable information of additional benefits
gained by implementing multidrug ARV regimens in PMTCT.
This might not be fully representative of results that would be
expected from comparable PMTCT interventions in other sites in
semi-urban or rural areas in Cameroon, where health workers
may be less skilled, and operational contexts vary considerably.
In this study, the proportion of children with low birth weight
was 22.3%. This proportion was greater than the 7.8% previously
reported in Cameroon among children born to uninfected women
[22], but was comparable to the figures reported in children born
to HIV infected mothers having received similar ARV regimens
for PMTCT in African settings with comparable HIV prevalence
[11,14]. The difference in weight observed between children born
to HIV-positive women that were enrolled in this study and
uninfected women in Cameroon could be due to their mothers’
HIV serological status. The in utero exposure of children enrolled
in this study to antiretroviral drugs could also be another
explanation to this discrepancy [14,23].
We observed three distinct feeding practices in our sample:
exclusive formula feeding (86%), exclusive breastfeeding (9%) and
mixed feeding (5%). Formula feeding of children born to HIV
infected women had been previously described as acceptable and
feasible in Yaounde [13]. The higher proportion of EFF observed
in this study compared to other African population could be
explained by a large number of mothers matching to AFASS
(Acceptable, Feasible, Affordable, Sustainable, Safe) criteria
according to WHO recommendations [24]. Formula feeding was
reported feasible in relatively resource-limited settings if adequate
water supply was available, and when women received intensive
education and counselling [25]. Concerning mixed feeding which
was found to be an important risk factor for infection or death, the
proportion reported was as low as the 5% reported in a clinical
research in Botswana [26]. A similar finding has been reported in
Table 2. Determinants of risk of progression to HIV-infection or death (Multivariate Cox proportional Hazards model) at the CNPS
hospital of Yaounde in Cameroon between 2004 and 2008.
N HR** 95% CI P HRa*** 95% CI P
Duration of treatment
$4 weeks before delivery 288 1 1
,4 weeks before delivery 106 3.6 2.2–5.8 0.001 1.1 0.5–2.4 0.8
Treatment
Regimen 1 (HAART) 66 1 1
Regimen 2 153 1.8 0.7–4.7 0.3 0.9 0.3–2.8 0.9
Regimen 3 94 2.7 0.9–7.1 0.05 1.3 0.4–3.7 0.7
Regimen 4 81 4.2 1.6–11 0.004 1.9 0.6–6.5 0.3
Feeding
Formula feeding 335 1 1
Exclusive breastfeeding 36 2.8 1.5–5.4 0.02 2.1 0.9–6.0 0.06
Mixed Feeding 23 6.9 3.9–12.4 0.0001 8.7 3.6–20.6 0.001
Birth weight
.2500 grams 305 1 1
#2500 grams 89 5.0 3.1–8.1 0.001 1.9 1.1–3.6 0.03
Prematurity*
No 332 1 1
Yes 62 4.3 2.6–7.0 0.0001 2.3 1.2–4.3 0.009
*(,37 weeks of gestation).
**Crude (Univariate).
***Adjusted (Multivariate).
doi:10.1371/journal.pone.0010411.t002
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feeding among a group of women who opted for formula feeding
was observed. Such women rarely modify their feeding option by
associating breastfeeding [27].
We observed programmatic changes in HAART eligibility
during implementation of the public health program that we
evaluated but this did not have an impact on MTCT rate in the
two periods. Also, final results of children were considered
regardless of the period since they were no difference in the
sensitivity of the 2 methods as concerns detection of HIV infection
at 6 weeks. The MTCT rate achieved with multidrug regimens at
6 weeks after birth was significantly lower than the 13.1% reported
with HIVNET 012 protocol in Yaounde [13]. The result was close
to the 7% reported in Botswana national PMTCT program [28].
It was also close to the 6.9% reported in a clinical trial in Malawi
with a drug regimen equivalent to regimen 2 in our study [29].
Comparable results were also reported in the ANRS ‘‘Ditrame
plus’’ study in Abidjan, where MTCT rates using protocols
identical to regimen 2 and 3 were respectively 8.9% (95%CI:
5.3%–12.3%) and 5.9% (95%CI: 3.4%–8.5%) among children
receiving FF. Duration of ARV regimens more than four weeks
was very important for a better reduction of MTCT risk. Influence
of a longer duration of antiretroviral prophylaxis on efficacy under
research conditions has been reported earlier in Co ˆte d’Ivoire [10]
and in Botswana [30]. Altogether, sc ARV regimens in routine
conditions in Cameroon showed a level of effectiveness compa-
rable to the one observed during research activities [15] and can
reduce the risk of MTCT to fewer than 7%. Therefore, our data
show that regimens recommended by WHO in developing
countries beyond sd-NVP, and outside of research settings, can
be effective in routine use, although MTCT rate is still far from
reaching the 5% target [31]. This should encourage key
stakeholders and health professionals in limited settings to
reinforce measures for increasing access to multidrug ARV
regimens. Between 6 weeks and 12 months, the postpartum
transmission due to breastfeeding was 25%. This was comparable
to 14% and 29% reported in studies in developing countries
[31,32]. The probability of infection or death at 12-month was
17%. This did not vary significantly when comparing EBF and
EFF groups. Infant mortality rates at 12-month were 7.5% and
20% respectively, among uninfected children and children found
infected at 6 weeks. By age of one year, infant mortality among
infected children was significantly higher. Early HIV-infection had
been previously reported associated with a greater mortality
among children [33]. In this study, the main risk factors of
progressing to HIV-infection or death included mixed-feeding,
pre-term birth and low-birth weight. These variables have also
been reported as risk factors of infection or death in Abidjan [11].
In summary, this study showed that multidrug antiretroviral
regimens recommended in 2004 were feasible and resulted in low
MTCT rates under routine conditions. Poor obstetrical outcomes
and mixed feeding appear as important operational risk factors
which can erode the benefits of new regimens in routine use. This
evaluation was made possible because early diagnosis of HIV-1
infection in children was available in Yaounde. However, it is
worth noting that early diagnosis is not routinely available in
health facilities nationwide. Hence, efforts made to effectively use
dried blood spot (DBS), which have shown a great impact in the
scaling-up of early diagnosis of HIV-1 need to be extended to the
hinterlands where HIV diagnosis in children less than 9 months
still remains inaccessible. Altogether, findings of this study could
push decision-makers to enhance commitment and support an
adequate and sustainable extension of the use of multidrug ARV
regimens nationwide, within the PMTCT scaling-up, and to
strengthen obstetrical care and infant nutrition in the context of
HIV in low-income countries. This could also be an opportunity to
improve mothers’ access to antiretroviral prophylaxis and
treatment and reduce HIV paediatric infections.
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